Cyprio
Created in 2017
- BETA
To investigate (B)
Some signals may appear as inconsistent with a regular activity Social networks
90 1,222Activities
Technologies
Entity types
Location
102 Av. Gaston Roussel, 93230 Romainville, France
Romainville
France
Employees
Scale: 2-10
Estimated: 2
SIREN
830373882Engaged corporates
3
1 3Added in Motherbase
5 years, 1 month ago
biotech Value proposition
Created in 2017, Cyprio is founded on ten years of research at the prestigious French institute for higher education in science and engineering, Ecole Supérieure de Physique et Chimie Industrielles de la ville de Paris (ESPCI Paris), with a strong expertise in the field of 3D cell culture, liver biology and drug development. This makes Cyprio the holder of a unique technology for fabrication of alginate liquid-core capsules containing 3D cellular models physiologically more relevant than traditional monolayer cell culture and compatible with high throughput screening applications.
Our first product "HepatoPearl" has been validated as a beneficial in vitro liver model for different applications from drug-drug interaction screening, chronic toxicity and metabolism of low clearance compounds to disease modelling. Now Cyprio is developing additional products to definitively change liver cell culture biology approaches towards more complex and more relevant, yet more robust, easier to handle and HTS compatible 3D cellular models.
3D cell culture, Organoids, Spheroids, Liver biology, and Liquid-core capsulesOriginal language
Created in 2017, Cyprio is founded on ten years of research at the prestigious French institute for higher education in science and engineering, Ecole Supérieure de Physique et Chimie Industrielles de la ville de Paris (ESPCI Paris), with a strong expertise in the field of 3D cell culture, liver biology and drug development. This makes Cyprio the holder of a unique technology for fabrication of alginate liquid-core capsules containing 3D cellular models physiologically more relevant than traditional monolayer cell culture and compatible with high throughput screening applications.
Our first product "HepatoPearl" has been validated as a beneficial in vitro liver model for different applications from drug-drug interaction screening, chronic toxicity and metabolism of low clearance compounds to disease modelling. Now Cyprio is developing additional products to definitively change liver cell culture biology approaches towards more complex and more relevant, yet more robust, easier to handle and HTS compatible 3D cellular models.
Cyprio
Removing the barriers of 3D Cell Culture. Based on 10 years of research, Cyprio aims to redefine cell culture thanks to its mammalian cells encapsulation technology
https://www.cyprio.fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 ESPCI Paris - PSL Startup accelerator & VC, Higher Education | ESPCI Paris - PSL Startup accelerator & VC, Higher Education | Not capitalistic Not partnership Event 21 Nov 2019 | | |
 Région Ile de France National and local authorities, Government Administration | Région Ile de France National and local authorities, Government Administration | Not capitalistic Partnership Event 20 Jun 2019 | | |
 Techstars Iowa Accelerator Startup accelerator & VC, Venture Capital & Private Equity | Techstars Iowa Accelerator Startup accelerator & VC, Venture Capital & Private Equity | Not capitalistic Not partnership Event 5 Sep 2019 | | |